St. Louis Pharmaceutical Company To Begin Selling New Painkiller

Photo courtesy of Creative Commons
Photo courtesy of Creative Commons

Mallinckrodt is banking on a new painkiller set to hit the market next year to make up for revenue that will be lost on its other major drugs whose patents are retiring. However, analysts say the company, which has its U.S. headquarters in the St. Louis area, could face painful competition in the drug marketplace.

Mark Trudeau, president and CEO of Mallinckrodt, said the company anticipates that Xartemis XR, a 12-hour extended-release painkiller that is a combination of oxycodone and acetaminophen, could generate “hundreds of millions in revenue.” The U.S. Food and Drug Administration is expected to rule on Xartemis in the next three months, and the pharmaceutical company is planning to heavily market the drug. Mallinckrodt already has added 150 to 200 contracted sales representatives to promote it, according to filings with the U.S. Securities and Exchange Commission.

Read more from the St. Louis Business Journal

Tags:, , , , , ,

Leave a Reply

Have you heard?

Missouri Business Alert is participating in CoMoGives2019!

Find out how we plan to use your gift to enhance training and programming for our students